Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Chemotherapy-induced cystoid macular edema in ovarian cancer
1Department of Obstetrics and Gynecology, Japan Community Health Care Organization Osaka Hospital and Osaka International Cancer Institute, Osaka City, Osaka
2Departmant of Gynecology, Osaka International Cancer Institute, Osaka City, Osaka
3Department of Obstetrics and Gynecology, Nippon life Hospital, Osaka City, Osaka (Japan)
*Corresponding Author(s): Y. Kiyohara E-mail: kiyoyumi000@hotmail.co.jp
Cystoid macular edema is a rare adverse event induced by chemotherapy that significantly reduces patient’s quality of life; however, symptoms of visual abnormalities may be indistinguishable from age-related changes. The authors report a case of cystoid macular edema that occurred during chemotherapy for recurrent ovarian cancer. The patient was treated with paclitaxel and carboplatin for six months; however, because of increased tumor size, the authors switched to paclitaxel and bevacizumab. Visual disturbance appeared about one month after the switch. The patient was diagnosed with cystoid macular edema and requested a change in her treatment regimen because of other adverse events, and the macular edema improved within about two months after the change.
Cystoid macular edema; Ovarian cancer; Paclitaxel; Bevacizumab.
Y. Kiyohara,T. Kimura,N. Hashimoto,Y. Ota,S. Kamiura. Chemotherapy-induced cystoid macular edema in ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(2);293-295.
[1] Bassi E., Loizzi V., Furino C., Martino R., Alessio G., Cormio G., et al.: “Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: A case report”. Mol. Clin. Oncol., 2017, 7, 285.
[2] Chelala E., Arej N., Antoun J., Kourie H.R., Zaarour K., Kattan J., et al.: “Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients”. Chemotherapy, 2017, 62, 199.
[3] Yokoe T., Fukada I., Kobayashi K., Shibayama T., Miyagi Y., Ito Y., et al.: “Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review”. Case Rep. Oncol., 2017, 10, 605.
[4] Rao R.C., Choudhry N.: “Cystoid macular edema associated with chemotherapy”. CMAJ, 2016, 188, 216.
[5] Koo N.K., Kim Y.C.: “A case of paclitaxel-induced maculopathy
treated with methazolamide”. Korean J. Ophthalmol., 2012, 26, 394.
[6] Hassall M.M., Andrew N.H.: “Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment
of taxane drug-induced cystoid macula oedema”. BMJ Case Rep.,
2016, 2016, 1136.
[7] Kim E.C., Ryu H.W., Lee H.J., Kim M.S.: “Bevacizumab eye drops delay corneal epithelial wound healing and increase the stromal response to epithelial injury in rats”. Clin. Exp. Ophthalmol., 2013, 41, 694.
[8] Dwivedi R., Tiroumal S.: “Possible Efficacy of Topical Dorzolamide in The Treatment of Paclitaxel-Related Cystoid Macular Edema”. Retin. Cases Brief Rep., 2018, 12, 75.
[9] Sridhar J., Shahlaee A., Ehmann D., Samara W.A., Rahimy E., Chiang A., et al.: “En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography Imaging of Taxane-Associated Cystoid Macular Edema”. Ophthalmic Surg. Lasers Imaging Retina, 2016, 47, 176.
[10] Nakao S., Ikeda Y., Emi Y., Ishibashi T.: “Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy”. Ophthalmic Surg. Lasers Imaging Retina, 2016, 47, 81.
[11] Modi D., Dubovy S.R.: “Non-leaking Cystoid Maculopathy Secondary to Systemic Paclitaxel”. Ophthalmic Surg. Lasers Imaging Retina, 2013, 44, 183.
[12] Kuznetcova T.I., Cech P., Herbort C.P.: “The mystery of angiographically silent macular oedema due to taxanes”. Int. Ophthalmol., 2012, 32, 299.
[13] Georgakopoulos C.D., Makri O.E., Vasilakis P., Exarchou A.: “Angiographically silent cystoid macular oedema secondary to paclitaxel therapy”. Clin. Exp. Optom., 2012, 95, 233.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top